- Home
- IGMS vs BYSI Comparison
IGMS vs BYSI Comparison
Compare IGMS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- BYSI
- Stock Information
- Founded
- IGMS 1993
- BYSI 2010
- Country
- IGMS United States
- BYSI United States
- Employees
- IGMS N/A
- BYSI N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- BYSI Health Care
- Exchange
- IGMS Nasdaq
- BYSI Nasdaq
- Market Cap
- IGMS 82.1M
- BYSI 67.3M
- IPO Year
- IGMS 2019
- BYSI 2017
- Fundamental
- Price
- IGMS $1.26
- BYSI $1.63
- Analyst Decision
- IGMS Hold
- BYSI
- Analyst Count
- IGMS 8
- BYSI 0
- Target Price
- IGMS $6.14
- BYSI N/A
- AVG Volume (30 Days)
- IGMS 172.4K
- BYSI 20.0K
- Earning Date
- IGMS 05-13-2025
- BYSI 05-12-2025
- Dividend Yield
- IGMS N/A
- BYSI N/A
- EPS Growth
- IGMS N/A
- BYSI N/A
- EPS
- IGMS N/A
- BYSI N/A
- Revenue
- IGMS $2,681,000.00
- BYSI N/A
- Revenue This Year
- IGMS $124.45
- BYSI N/A
- Revenue Next Year
- IGMS $45.07
- BYSI N/A
- P/E Ratio
- IGMS N/A
- BYSI N/A
- Revenue Growth
- IGMS 27.36
- BYSI N/A
- 52 Week Low
- IGMS $0.92
- BYSI $0.98
- 52 Week High
- IGMS $22.50
- BYSI $2.97
- Technical
- Relative Strength Index (RSI)
- IGMS 51.89
- BYSI 48.29
- Support Level
- IGMS $1.13
- BYSI $1.62
- Resistance Level
- IGMS $1.42
- BYSI $1.77
- Average True Range (ATR)
- IGMS 0.09
- BYSI 0.09
- MACD
- IGMS 0.01
- BYSI -0.01
- Stochastic Oscillator
- IGMS 52.94
- BYSI 5.88
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.